News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
12-Mar-2010 - The Australian oncology market’s high value and growth opportunities have made it an attractive arena for drug developers to enter. Top 20 cancer therapy brands sales totaled $545m in Australia in 2008, growing at a CAGR of 30% since 2005. Although this growth is expected to slow down ...
11-Mar-2010 - The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008. This rapid market expansion presents significant opportunities for pharmaceutical companies who are able to develop new therapies to address the unmet clinical ...
04-Mar-2010 - Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107bn in ...
01-Mar-2010 - Top pharmaceutical and biotech companies face a major slow down in sales growth over 2008–14 according to a new report by independent business analyst Datamonitor. The report title “Pharmaceutical Company Outlook to 2014” considers the forecast performance of the world’s biggest pharmaceutical ...
19-Feb-2010 - An increasing number of Pharmaceutical (Pharma) companies are targeting emerging markets. Indonesia and the Philippines are starting to gain considerable attention thanks to their burgeoning healthcare systems. A recent report by independent market analyst Datamonitor shows that Pharma’s interest ...
17-Dec-2009 - Large-scale M&A activity remains an integral strategy of Big Pharma and will contribute nearly two-thirds of peer set sales growth over 1995–2014. Analysis of the 22 largest Big Pharma M&A events since 1995 demonstrates that there are two distinct acquisition types: the purchase of smaller target ...
18-Nov-2009 - As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff’, Big Pharma is busy implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines. In an effort to mitigate the impact, Big ...
25-Sep-2009 - Within the pharmaceutical sector, vaccines were traditionally regarded as low-margin products. However, with the decline of Big Pharma’s traditional small molecule blockbuster model and a marked swing towards biologics, vaccines have regained appreciation as generics-proof revenue drivers. This ...
10-Aug-2009 - Antipsychotic pipeline developers have been in the spotlight in recent weeks with the announcement of the FDA approval of Johnson & Johnson’s Invega Sustenna (paliperidone palmitate), FDA panel backing for Schering-Plough’s Saphris (asenapine) and the end of Lundbeck and Solvay’s collaboration ...
30-Jul-2009 - As pay-for-delay agreements look to be on the way out of the pharmaceutical industry in Europe and the US, a new report by independent market analyst Datamonitor forecasts that the number of authorized generics (AG) agreements will grow, in tandem with the increasing convergence between branded ...
© 1997-2024 LUMITOS AG, All rights reserved